Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SEHK:2196 Stock Report

Market Cap: HK$65.4b

Shanghai Fosun Pharmaceutical (Group) Management

Management criteria checks 2/4

Shanghai Fosun Pharmaceutical (Group)'s CEO is Deyong Wen, appointed in Jan 2022, has a tenure of 2.92 years. total yearly compensation is CN¥10.00M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth HK$2.55M. The average tenure of the management team and the board of directors is 2.2 years and 3.5 years respectively.

Key information

Deyong Wen

Chief executive officer

CN¥10.0m

Total compensation

CEO salary percentage25.9%
CEO tenure2.9yrs
CEO ownership0.004%
Management average tenure2.2yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Deyong Wen's remuneration changed compared to Shanghai Fosun Pharmaceutical (Group)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥2b

Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥10mCN¥3m

CN¥2b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥8mCN¥2m

CN¥4b

Compensation vs Market: Deyong's total compensation ($USD1.37M) is above average for companies of similar size in the Hong Kong market ($USD789.03K).

Compensation vs Earnings: Deyong's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Deyong Wen (53 yo)

2.9yrs

Tenure

CN¥9,997,000

Compensation

Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Kexin Wang
Executive Co-Chairman3yrsCN¥15.25m0.012%
HK$ 8.0m
Yifang Wu
Executive Chairman8.3yrsCN¥12.14m0.046%
HK$ 29.8m
Deyong Wen
Joint President2.9yrsCN¥10.00m0.0039%
HK$ 2.6m
Xiaohui Guan
Executive Vice Chairman3yrsCN¥9.14m0.011%
HK$ 7.2m
Rongli Feng
Executive President & Chief Human Resources Officeless than a yearno data0.0031%
HK$ 2.0m
Jing Li
Executive President and CEO of Established Medicines Manufacturing & Supply Divisionno datano data0.0031%
HK$ 2.0m
Wang Xingli
Executive President1.9yrsno datano data
Wenjie Zhang
Executive President & Co-CEO of Innovative Drug Division1.9yrsno datano data
Zhanyu Chen
Senior VP & CFOless than a yearno datano data
Jia Yan
Director of the Accounting Departmentno datano datano data
Dongjiu Li
Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee3.8yrsno data0.0016%
HK$ 1.1m
Donghua Wang
Senior VP & Chief Strategic Enabler4.2yrsno data0.0031%
HK$ 2.0m

2.2yrs

Average Tenure

55yo

Average Age

Experienced Management: 2196's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kexin Wang
Executive Co-Chairman3yrsCN¥15.25m0.012%
HK$ 8.0m
Yifang Wu
Executive Chairman8.3yrsCN¥12.14m0.046%
HK$ 29.8m
Deyong Wen
Joint President2.3yrsCN¥10.00m0.0039%
HK$ 2.6m
Xiaohui Guan
Executive Vice Chairman3yrsCN¥9.14m0.011%
HK$ 7.2m
Guliang Tang
Independent Non-Executive Director5.5yrsCN¥392.00kno data
Qiyu Chen
Non-Executive Director19.6yrsno data0.0043%
HK$ 2.8m
Xiaoliang Xu
Non-Executive Director5.5yrsno datano data
Ling Li
Independent Non-Executive Director5.5yrsCN¥392.00kno data
Tze Shan Yu
Independent Non-Executive Director3.5yrsCN¥392.00kno data
Yuqing Chen
Non-Executive Directorless than a yearno data0.0058%
HK$ 3.8m
Quandi Wang
Independent Non-Executive Director3.5yrsCN¥392.00kno data
Bing Chen
Chief Supervisor1.5yrsno datano data

3.5yrs

Average Tenure

54yo

Average Age

Experienced Board: 2196's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 14:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.
Yang HuangBofA Global Research